Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridion for reversal of rocuronium-induced blockade in infants
NCT02708056Phase 4Completed
- Sponsor
- Baskent University
- Start
- Jan 2015
- Primary completion
- Feb 2016
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Baskent University. Primary endpoint: Train of Four at 1 year. Started Jan 2015; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02708056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708056.